权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology

Fontan 生理学中肺血管扩张剂治疗的临床和血流动力学反应机制

基本信息

批准号：
10542724
负责人：
Alexander Egbe
金额：
$ 64万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-12-20 至 2026-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10542724
关键词：
Acute Aerobic Age Years Arteries Blood Blood Vessels Cardiac Catheterization Procedures Cardiovascular system Central venous pressure Cessation of life Chronic Cirrhosis Clinical Clinical Trials Complex Cyclic GMP Data Detection Development Diagnosis Early Diagnosis Early treatment Endothelium Exercise Exercise Test Exposure to Failure Fontan Procedure Functional disorder Future Glomerular Filtration Rate Goals Grant Health Care Costs Heart failure Impairment Intestines Kidney Kidney Failure Knowledge Life Link Liver Lung Magnetic Resonance Elastography Minnesota Mission Morbidity - disease rate Nitric Oxide Organ Outcome Outcome Assessment Oxygen Consumption Patients Peripheral Persons Physiology Placebos Population Portal vein structure Prevention Prevention therapy Protein-Losing Enteropathies Public Health Publishing Pulmonary Circulation Pulmonary Vascular Resistance Quality of life Questionnaires Randomized Research Risk Factors Severities Signal Transduction Symptoms Testing Therapeutic United States National Institutes of Health Vascular Endothelium Vasodilator Agents Venous burden of illness cohort congenital heart disorder disability disease diagnosis endothelial dysfunction evidence base exercise capacity hemodynamics improved indexing innovation liver stiffness mortality novel therapeutics palliation phosphodiesterase V premature prevent pulmonary vascular disorder reactive hyperemia response tonometry treatment strategy

项目摘要

PROJECT SUMMARY/ABSTRACT Congenital heart disease (CHD) is the leading cause of cardiovascular death in people less than 50 years of age, and most of the premature cardiovascular deaths occur in people with complex CHD. Although the Fontan operation is an effective palliation for complex CHD, it creates a unique physiology characterized by systemic venous congestion and end-organ dysfunction, which leads to premature death from circulatory failure (median survival ~40 years). One of the mechanisms leading to this suboptimal outcome begins with impaired nitric oxide signaling, leading to endothelial dysfunction and pulmonary vascular disease (PVD), and in turn, end- organ dysfunction and death. The therapeutic benefits of chronic pulmonary vasodilator therapy for PVD in people with Fontan palliation have not been consistent across trials, and this may be related to the lack well- defined criteria for PVD diagnosis in Fontan physiology, and lack of understanding regarding the underlying mechanisms. Recent data show that assessment of pulmonary vascular reserve during exercise improves detection of PVD, and that impairment in pulmonary vascular reserve correlates with severity of endothelial dysfunction and end-organ dysfunction. However, it remains unclear whether pulmonary vasodilators can improve pulmonary vascular reserve in these patients, or what the mechanisms might be. Such data will be critical for the development novel therapies for prevention and treatment of end-organ dysfunction due to PVD, an important risk factor for mortality in the Fontan population. The long-term goal is to delay the onset of end- organ dysfunction and mortality from systemic venous congestion, through early diagnosis and treatment of hemodynamic derangements in Fontan physiology. The overall objective for this application is to determine the mechanisms by which enhancement in nitric oxide signaling might improve pulmonary vascular reserve and end-organ function in Fontan physiology. The central hypothesis is that enhancement in nitric oxide signaling through treatment with phosphodiesterase-5 inhibition (PDE5i) will improve pulmonary vascular reserve, and endothelial and end-organ function. This hypothesis will be tested by pursuing two specific aims: (1) Determine the mechanism of response to pulmonary vasodilator therapy in Fontan physiology; (2) Determine the mechanism of improvement in end-organ function, aerobic capacity and quality of life (QOL) outcomes after pulmonary vasodilator therapy. For the first aim, 80 subjects will be randomized 1:1 to PDE5i or placebo, and invasive exercise test and peripheral artery tonometry will be performed before and after 52 weeks of therapy. For the second aim, multi-domain outcome assessment (liver, kidney, gut, aerobic capacity, and QOL metrics) will be assessed before and after therapy. This proposal is innovative and significant as it will delineate the mechanism of response to pulmonary vasodilators, and in turn, enable targeting of these mechanisms with current and novel therapies to delay the onset of end-organ dysfunction and circulatory failure.